MX2021009555A - Ligandos de pseudocinasa tyk2. - Google Patents

Ligandos de pseudocinasa tyk2.

Info

Publication number
MX2021009555A
MX2021009555A MX2021009555A MX2021009555A MX2021009555A MX 2021009555 A MX2021009555 A MX 2021009555A MX 2021009555 A MX2021009555 A MX 2021009555A MX 2021009555 A MX2021009555 A MX 2021009555A MX 2021009555 A MX2021009555 A MX 2021009555A
Authority
MX
Mexico
Prior art keywords
ligands
tyk2 pseudokinase
tyk2
pseudokinase ligands
disorders
Prior art date
Application number
MX2021009555A
Other languages
English (en)
Inventor
Jason Harris
Raju Mohan
John Nuss
Shendong Yuan
Original Assignee
Ventyx Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventyx Biosciences Inc filed Critical Ventyx Biosciences Inc
Publication of MX2021009555A publication Critical patent/MX2021009555A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

En el presente documento se describen ligandos de pseudocinasa TYK2 y métodos para usar ligandos de pseudocinasa TYK2 en el tratamiento de enfermedades, trastornos o afecciones. También se describen en el presente documento composiciones farmacéuticas que contienen dichos compuestos.
MX2021009555A 2019-02-07 2020-02-07 Ligandos de pseudocinasa tyk2. MX2021009555A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962802642P 2019-02-07 2019-02-07
PCT/US2020/017314 WO2020163778A1 (en) 2019-02-07 2020-02-07 Tyk2 pseudokinase ligands

Publications (1)

Publication Number Publication Date
MX2021009555A true MX2021009555A (es) 2021-10-13

Family

ID=71947508

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009555A MX2021009555A (es) 2019-02-07 2020-02-07 Ligandos de pseudocinasa tyk2.

Country Status (12)

Country Link
US (1) US20220135567A1 (es)
EP (1) EP3920931A4 (es)
JP (1) JP2022519696A (es)
KR (1) KR20210124409A (es)
CN (1) CN113677347A (es)
AU (1) AU2020218267A1 (es)
BR (1) BR112021015616A2 (es)
CA (1) CA3129438A1 (es)
IL (1) IL285429A (es)
MX (1) MX2021009555A (es)
SG (1) SG11202108619SA (es)
WO (1) WO2020163778A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3870579A4 (en) 2018-10-22 2022-10-19 Alumis Inc. TYK2 INHIBITORS AND THEIR USES
CN113874021A (zh) 2019-03-26 2021-12-31 温缇克斯生物科学公司 Tyk2假激酶配体
TW202128698A (zh) 2019-11-08 2021-08-01 美商凡帝克斯生物科學公司 Tyk2假激酶配位體
JP2023541203A (ja) * 2020-09-16 2023-09-28 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
CN117043164A (zh) * 2021-01-19 2023-11-10 安锐生物医药科技(广州)有限公司 咪唑并哒嗪或吡唑并嘧啶化合物和组合物
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2516824A1 (en) * 2003-02-28 2004-09-10 Teijin Pharma Limited Pyrazolo[1,5-a]pyrimidine derivatives
TW201720828A (zh) * 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
TW202321243A (zh) * 2017-03-08 2023-06-01 美商林伯士拉克許米公司 Ｔｙｋ２抑制劑之生產方法
JP7228318B6 (ja) * 2017-05-22 2023-03-10 エフ． ホフマン－ラ ロシュ アーゲー 処置用化合物及び組成物、並びにその使用方法
JP7216705B2 (ja) * 2017-07-28 2023-02-02 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用方法
EP3849981B1 (en) * 2018-09-10 2023-02-01 Eli Lilly and Company Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
AU2019360941A1 (en) * 2018-10-15 2021-04-29 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
AR117177A1 (es) * 2018-12-10 2021-07-14 Lilly Co Eli DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa

Also Published As

Publication number Publication date
KR20210124409A (ko) 2021-10-14
BR112021015616A2 (pt) 2021-11-09
SG11202108619SA (en) 2021-09-29
WO2020163778A1 (en) 2020-08-13
EP3920931A1 (en) 2021-12-15
JP2022519696A (ja) 2022-03-24
AU2020218267A1 (en) 2021-09-30
CA3129438A1 (en) 2020-08-13
US20220135567A1 (en) 2022-05-05
IL285429A (en) 2021-09-30
CN113677347A (zh) 2021-11-19
EP3920931A4 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2022016434A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
MX2021013602A (es) Inhibidores de jak.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
MX2022000712A (es) Moduladores de nlrp3.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
EP4218789A3 (en) Compositions for colon cleansing and the treatment of gastrointestnal disorders